查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
北美传染病即时护理分子检测市场规模及预测（2021-2031）、区域份额、趋势和成长机会分析报告
市场调查报告书
商品编码
1498571

北美传染病即时护理分子检测市场规模及预测（2021-2031）、区域份额、趋势和成长机会分析报告

North America Point-of-Care Molecular Testing for Infectious Diseases Market Size and Forecast (2021-2031), Regional Share, Trend, and Growth Opportunity Analysis Report
出版日期: | 出版商: The Insight Partners | 英文 162 Pages | 订单完成后即时交付

价格

全球北美传染病即时分子检测市场预计将从 2023 年的 10.9 亿美元增至 2031 年的 26.3 亿美元。

本报告中提出的北美传染病即时分子检测市场预测可以帮助该市场的利害关係人规划其成长策略。传染病发病率的激增和对快速诊断解决方案的偏好是推动市场发展的关键因素。然而，报销不足阻碍了北美传染病即时分子检测市场的成长。

北美传染病即时护理分子检测市场的市场机会

研究与开发（R&D）是製药和生物製药公司的重要组成部分。研发使市场参与者能够开发具有巨大医疗和商业潜力的各种治疗应用的新产品。下表显示了基于合约、补助金和 NIH 采用的其他资助机制的各种研究和疾病类别的年度资助。

  • 表 1. 传染病与资金

研究/疾病领域 2019 年（百万美元） 2020 年（百万美元） 2021 年（百万美元） 2022 年（百万美元）

新兴传染病 2,950 4,867 5,069 4,318

传染病 6,313 8,301 8,599 8,019

性传染感染 354 394 404 419

注意：货币的当前兑换率已被考虑。

资料来源：年度报告与 Insight Partners 分析

为了应对实验室能力和分子检测试剂的短缺，加上传染病病例的不断增加，诊断检测製造商提供了快速且易于使用的设备来促进实验室外检测。以下是北美传染病即时检测市场製造商采取的一些关键融资措施的清单。

8 月，美国卫生与公众服务部 (HHS) 授予 Cue Health 一份价值约 2800 万美元的新合同，隶属于美国战略准备和响应管理局下属的生物医学高级研究与开发局 (BARDA)。该合约旨在开发一种分子多重测试，可用于 COVID-19、呼吸道合胞病毒 (RSV) 和甲型/乙型流感的即时护理 (POC) 和非处方 (OTC) 目的诊断。 Cue 的测试将在近 25 分钟内为连接的智慧型装置提供结果，同时检测和区分 COVID-19、呼吸道合胞病毒 (RSV)、甲型流感和乙型流感。

2023 年 1 月，非营利性行为科学倡议组织 19 to Zero 透过教育补助金获得了 BD 的资助，用于初级保健环境中的即时测试试点。在获得财务奖励的同时，还提供了多个 BD Veritor Plus 系统分析仪和 BD Veritor 快速检测系统，以促进甲型和乙型流感、RSV、SARS-CoV-2、A 组链球菌、和三重。

2022 年 3 月，全球抗爱滋病、疟疾和结核病基金对加拿大向全球基金的 COVID-19 应对机制 (C19RM) 捐款 6,000 万加元（4,399 万美元）的决定表示讚赏。这笔资金用于支持向低收入和中等收入国家提供救生诊断测试、治疗和个人防护装备 (PPE) 的努力。

2021年9月，拜登-哈里斯政府投资21亿美元，加强美国公共卫生和医疗保健部门的感染控制和预防活动。拜登-哈里斯政府透过疾病预防控制中心运作，投资于美国救援计划，以解决美国各州、地方和地区卫生部门以及其他合作组织有关美国传染病的问题。

因此，对传染病诊断研发和资金的日益关注预计将为未来几年北美传染病市场即时检测的成长创造有利可图的机会。

阻碍北美传染病市场即时检测的因素

如果存在资料不能表明新测试的成本效益或证明现有测试昂贵，报销的可能性仍然很低。因此，大多数诊断测试的报销率较低，阻碍了製造公司投入大量资源来开发新测试。报销新的或昂贵的诊断测试的困难和担忧对诊断技术的广泛部署构成了重大挑战。在美国，报销包括第三方付款人对医疗服务或条件进行编码以确定付款水准的承保范围。对于使用当前程序术语 (CPT) 代码的门诊测试，医疗保险覆盖咨询委员会在诊断测试覆盖方面促进医疗保险和医疗补助服务中心 (CMS)，包括确定足够的证据和健康福利。然而，大多数医疗保险报销决定都是在当地而不是在全国范围内做出的。诊断测试的覆盖范围因地区而异。此外，缺乏确定覆盖范围的标准可能会挑战新诊断产品的开发和可用性。

在某些情况下，报销不包括测试费用，这限制了实验室提供测试并降低了测试的可用性和使用。在其他情况下，检测费用可能很高，但可能会给患者留下相当大的成本，这限制了医生定期进行检测。

依疾病类型，北美传染病即时分子检测市场分为HIV检测、流感检测、性传染病检测、C型肝炎病毒检测、热带疾病检测、呼吸道感染检测、医院获得性感染、链球菌等。根据分子诊断，市场进一步分为聚合酶连锁反应（PCR）、等温核酸扩增技术（INAAT）等。 2023 年，呼吸道感染检测领域占据最大的市场。

依技术划分，市场分为侧流分析、试纸、微流体、分子诊断、免疫分析、固相等。 2023 年，侧流分析领域占据最大的市场份额。

从样本来看，市场分为血液样本、尿液样本、鼻口咽拭子等。 2023 年，血液样本细分市场占据最大市场份额。

就最终用户而言，市场分为医院和诊所、家庭护理机构、门诊和紧急护理设施、疗养院和辅助生活设施、研究实验室和诊断中心。市场根据医院和诊所进一步分为临床实验室、专业医师办公室等。 2023 年，医院和诊所领域占据最大的市场。

北美传染病床边分子检测市场：区域概览

传染病的日益普及、老年人口的增加以及主要参与者推出的产品数量激增是美国传染病即时检测市场成长的主要因素。老化是传染病的重要危险因素，因为 60 岁以上的人免疫力可能会下降。根据人口资料局2020年发布的研究，2020年美国65岁以上人口为5500万，预计到2060年将达到9,500万。例如，2021 年 3 月，美国食品药物管理局 (FDA) 授权 Binx Health IO CT/NG Assay 用于社区诊所、紧急护理机构和门诊医疗机构；它是第一个用于诊断衣原体和淋病感染的 POC 检测产品。

在准备北美传染病即时分子检测市场报告时提到的一些主要一手和二手来源包括世界银行数据、国家卫生服务体系 (NHS)、美国卫生与公众服务部(HHS) 和 WHO（世界卫生组织）。

目录

第 1 章：简介

第 2 章：执行摘要

  • 重要见解

第 3 章：研究方法

  • 二次研究
  • 初步研究
  • 假设的提出
    • 宏观经济因素分析：
    • 显影基数：
    • 数据三角测量：
    • 国家级资料：

第 4 章：北美传染病即时护理分子检测市场格局

  • 概述
  • PEST分析

第 5 章：北美传染病即时护理分子检测市场 - 主要市场动态

  • 北美传染病即时护理分子检测市场 - 主要市场动态
  • 市场驱动因素
    • 传染病发生率激增
    • 对快速诊断解决方案的偏好
  • 市场限制
    • 报销不足的情况
  • 市场机会
    • 日益关注传染病诊断的研发与资金
  • 未来的趋势
    • 产品批准和发布数量不断增加
  • 驱动因素和限制的影响：

第 6 章：北美传染病即时护理分子检测市场分析

  • 北美传染病床边分子检测市场收入，2021-2031年
  • 北美传染病即时护理分子检测市场预测与分析
  • 按公司分類的市占率分析 (2023)
  • 定价分析
  • COVID-19 前后的影响
  • 产品/公司的智慧财产权
    • POC专利申请
  • 新公司进入传染病应用护理点测试市场

第 7 章：北美传染病即时护理分子检测市场分析 - 按疾病

  • 爱滋病毒检测
  • 流感检测
  • 性传染病检测
  • 丙型肝炎病毒检测
  • 热带疾病检测
  • 呼吸道感染检测
  • 院内感染
  • 链球菌属
  • 其他的

第 8 章：北美传染病即时护理分子检测市场分析 - 按技术

  • 侧流层析
  • 量油尺
  • 微流控
  • 分子诊断
  • 免疫测定
  • 固相
  • 其他的

第 9 章：北美传染病即时护理分子检测市场分析 - 透过处方检测

  • 基于处方的测试
  • 场外测试

第 10 章：北美传染病即时护理分子检测市场分析 - 依样本

  • 血液样本
  • 尿液样本
  • 鼻和口咽拭子样本
  • 其他的

第 11 章：北美传染病即时护理分子检测市场分析 - 按下最终用户

  • 医院和诊所
  • 家庭护理设置
  • 门诊和紧急护理设施
  • 疗养院及辅助生活设施
  • 研究实验室
  • 诊断中心

第 12 章：北美传染病即时护理分子检测市场分析 - 按配销通路

  • 电子商务平台
  • 零售通路和药房
  • 其他的

第 13 章：北美传染病即时护理分子检测市场 - 国家分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

第 14 章：北美传染病即时护理分子检测市场 - 产业格局

  • 概述
  • 北美传染病床边分子检测市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 15 章：公司简介

  • Abbott Laboratories
  • Agilent Technologies Inc
  • Becton Dickinson and Co
  • Bio-Rad Laboratories Inc
  • Cardinal Health Inc
  • Danaher Corp
  • Cue Health Inc
  • QuidelOrtho Corp
  • Thermo Fisher Scientific Inc
  • F. Hoffmann-La Roche Ltd

第 16 章：附录

Product Code: TIPRE00039163

The global North America point-of-care molecular testing for infectious diseases market is expected to reach US$ 2.63 billion in 2031 from US$ 1.09 billion in 2023. The market is estimated to grow with a CAGR of 11.1% from 2023 to 2031.

The North America point-of-care molecular testing for infectious diseases market forecast presented in this report can help stakeholders in this marketplace plan their growth strategies. The surging prevalence of infectious diseases and preference for rapid diagnostic solutions are the key factors propelling the market development. However, inadequate reimbursement scenarios impede the North America point-of-care molecular testing for infectious diseases market growth.

Market Opportunities of North America Point-Of-Care Molecular Testing For Infectious Diseases Market

Research and development (R&D) is an essential component of pharmaceutical and biopharmaceutical companies. R&D enables market players to develop new products for various therapeutic applications with significant medical and commercial potential. The following table displays the annual funding for various research and disease categories based on contracts, grants, and other funding mechanisms adopted by the NIH.

  • Table 1. Infectious Diseases and Fundings

Research/Disease Areas 2019 (US$ Million) 2020 (US$ Million) 2021 (US$ Million) 2022 (US$ Million)

Emerging Infectious Diseases 2,950 4,867 5,069 4,318

Infectious Diseases 6,313 8,301 8,599 8,019

Sexually Transmitted Infections 354 394 404 419

Note: The current conversion rate is considered for the currencies.

Source: Annual Reports and The Insight Partners Analysis

In response to the shortage of laboratory capabilities and molecular testing reagents, coupled with the rising cases of infectious diseases, diagnostic testing manufacturers offer fast and easy-to-use devices to facilitate out-of-laboratory testing. Following is a list of a few key funding initiatives undertaken by manufacturers in the North America point-of-care testing for infectious diseases market.

In August, the US Department of Health and Human Services (HHS) awarded Cue Health a new contract worth ~US$ 28 million under the Biomedical Advanced Research and Development Authority (BARDA), a division of the Administration for Strategic Preparedness and Response. The contract was presented to develop a molecular multiplex test that can be used for point-of-care (POC) and over-the-counter (OTC) purposes for COVID-19, respiratory syncytial virus (RSV), and influenza A/B diagnoses. Cue's test would provide results to linked smart devices in nearly 25 minutes, simultaneously detecting and differentiating between COVID-19, respiratory syncytial virus (RSV), influenza A, and influenza B.

In January 2023, 19 to Zero, a non-profit behavioral sciences initiative group, received financing from BD through an educational grant for a point-of-care testing pilot in the primary care environment. A financial award was accompanied by the provision of multiple BD Veritor Plus System Analyzers and BD Veritor System for Rapid Detection Assays to facilitate point-of-care diagnostic testing for influenza A and B, RSV, SARS-CoV-2, Group A Strep, and triplex.

In March 2022, the Global Fund to Fight AIDS, Malaria, and Tuberculosis acclaimed the decision by Canada to contribute CAD 60 million (US$ 43.99 million) to the Global Fund's COVID-19 Response Mechanism (C19RM). The funding was provided to support efforts made to provide life-saving diagnostic tests, treatments, and personal protective equipment (PPE) to low- and middle-income countries.

In September 2021, the Biden-Harris Administration invested US$ 2.1 billion to enhance infection control and prevention activities across the US public health and healthcare sectors. The Biden-Harris administration, operating through the CDC, invested in US rescue programs to address state, local, and territorial health departments and other partner organizations regarding infectious diseases in the US.

Thus, rising focus on R&D and funding in infectious disease diagnostics is expected to create lucrative opportunities for the growth of North American point-of-care testing in the infectious disease market in the coming years.

Factor Hampering North American Point-Of-Care Testing In The Infectious Disease Market

The possibility of reimbursement remains low if there exists data that does not indicate the cost-effectiveness of new tests or prove the existing tests are expensive. Thus, low reimbursement rates for most diagnostic tests discourage manufacturing companies from investing large resources in developing new tests. Difficulties and concerns about reimbursing new or expensive diagnostic tests pose significant challenges to the widespread deployment of diagnostic technologies. In the US, reimbursement comprises coverage by third-party payers coding health services or conditions to determine payment level. For outpatient tests with Current Procedural Terminology (CPT) codes, the Medicare Coverage Advisory Committee promotes the Centers for Medicare & Medicaid Services (CMS) regarding diagnostic test coverage, including determining sufficient evidence and health benefits. However, most Medicare reimbursement decisions are made locally and not nationally. Coverage for diagnostic tests differs as per region. Also, the lack of standards in determining coverage can challenge the development and availability of a new diagnostic product.

In some cases, the reimbursement does not cover test costs, which limits laboratories in offering the test and reduces test availability and use. In other cases, test charges may be high but may leave a considerable cost to the patient, which limits physicians from ordering the test routinely.

Based on disease, the North America point-of-care molecular testing for infectious diseases market is divided into HIV testing, influenza testing, sexually transmitted diseases testing, hepatitis C virus testing, tropical diseases testing, respiratory infection testing, hospital-acquired infections, strep, and others. The market is further divided on the basis of molecular diagnostics into polymerase chain reactions (PCR), isothermal nucleic acid amplification technology (INAAT), and others. The respiratory infection testing segment held the largest market share in 2023.

By technology, the market is segmented into lateral flow assay, dipsticks, microfluidics, molecular diagnostics, immunoassays, solid phase, and others. The lateral flow assay segment held the largest share of the market in 2023.

In terms of sample, the market is segmented into blood samples, urine samples, nasal and oropharyngeal swabs, and others. The blood sample segment held the largest market share in 2023.

In terms of end user, the market is segmented into hospitals and clinics, home care settings, ambulatory and urgent care facilities, nursing homes and assisted living facilities, research laboratories, and diagnostics centers. The market is further divided on the basis of hospitals and clinics into clinical laboratories, professional physician offices, and others. The hospitals and clinics segment held the largest market share in 2023.

North America Point-Of-Care Molecular Testing for Infectious Diseases Market: Regional Overview

The increasing prevalence of infectious diseases, the rising geriatric population, and a surging number of product launches by key players are the primary contributors to the point-of-care testing for infectious diseases market growth in the US. Aging is a prominent risk factor for infectious diseases, as people aged more than 60 may have compromised immunity. According to a study published by the Population Reference Bureau in 2020, the population of individuals aged 65 and above was 55 million in the US in 2020, and the number is expected to reach 95 million by 2060. Regulatory agencies in the US rigorously monitor the development of point-of-care (POC) testing products. For instance, in March 2021, the US Food Drug Administration (FDA) authorized Binx Health IO CT/NG Assay for community-based clinics, urgent care settings, and outpatient healthcare facilities; it is the first POC testing product for diagnosing chlamydial and gonorrheal infections.

A few of the major primary and secondary sources referred to while preparing the report on the North America point-of-care molecular testing for infectious diseases market are the World Bank Data, National Health Service (NHS), US Department of Health and Human Services (HHS), and WHO (World Health Organization).

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
  • 3.3 Hypothesis formulation
    • 3.3.1 Macro-economic factor analysis:
    • 3.3.2 Developing base number:
    • 3.3.3 Data Triangulation:
    • 3.3.4 Country level data:

4. North America Point-of-Care Molecular Testing for Infectious Diseases Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Key Market Dynamics

  • 5.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Surging Prevalence of Infectious Diseases
    • 5.2.2 Preference for Rapid Diagnostic Solutions
  • 5.3 Market Restraints
    • 5.3.1 Inadequate Reimbursement Scenario
  • 5.4 Market Opportunities
    • 5.4.1 Increasing Focus on R&D and Funding in Infectious Disease Diagnostics
  • 5.5 Future Trends
    • 5.5.1 Rising Number of Product Approvals and Launches
  • 5.6 Impact of Drivers and Restraints:

6. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis

  • 6.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue (US$ Million), 2021-2031
  • 6.2 North America Point-of-Care Molecular Testing for Infectious Diseases Market Forecast and Analysis
  • 6.3 Market Share Analysis, By Companies (2023)
  • 6.4 Pricing Analysis
  • 6.5 Pre and Post COVID-19 Impact
  • 6.6 Intellectual Property Rights of Products/Companies
    • 6.6.1 POC Patent Filing
  • 6.7 Novel Companies Entering the Point of Care Testing Market For Infectious Diseases Application

7. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Diseases

  • 7.1 HIV Testing
    • 7.1.1 Overview
    • 7.1.2 HIV Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Influenza Testing
    • 7.2.1 Overview
    • 7.2.2 Influenza Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Sexually Transmitted Diseases Testing
    • 7.3.1 Overview
    • 7.3.2 Sexually Transmitted Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
      • 7.3.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sexually Transmitted Diseases Testing
  • 7.4 Hepatitis C Virus Testing
    • 7.4.1 Overview
    • 7.4.2 Hepatitis C Virus Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Tropical Diseases Testing
    • 7.5.1 Overview
    • 7.5.2 Tropical Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
      • 7.5.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Tropical Diseases Testing
  • 7.6 Respiratory Infection Testing
    • 7.6.1 Overview
    • 7.6.2 Respiratory Infection Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.7 Hospital Acquired Infections
    • 7.7.1 Overview
    • 7.7.2 Hospital Acquired Infections: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.8 Strep
    • 7.8.1 Overview
    • 7.8.2 Strep: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.9 Others
    • 7.9.1 Overview
    • 7.9.2 Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)

8. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Technology

  • 8.1 Lateral Flow Assay
    • 8.1.1 Overview
    • 8.1.2 Lateral Flow Assay: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Dipsticks
    • 8.2.1 Overview
    • 8.2.2 Dipsticks: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Microfluidics
    • 8.3.1 Overview
    • 8.3.2 Microfluidics: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Molecular Diagnostics
    • 8.4.1 Overview
    • 8.4.2 Molecular Diagnostics: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
      • 8.4.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Molecular Diagnostics
        • 8.4.2.1.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Polymerase Chain Reactions (PCR)
  • 8.5 Immunoassays
    • 8.5.1 Overview
    • 8.5.2 Immunoassays: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Solid Phase
    • 8.6.1 Overview
    • 8.6.2 Solid Phase: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.7 Others
    • 8.7.1 Overview
    • 8.7.2 Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Prescription Testing

  • 9.1 Prescription Based Testing
    • 9.1.1 Overview
    • 9.1.2 Prescription Based Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 OTC Testing
    • 9.2.1 Overview
    • 9.2.2 OTC Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)

10. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Sample

  • 10.1 Blood Sample
    • 10.1.1 Overview
    • 10.1.2 Blood Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Urine Sample
    • 10.2.1 Overview
    • 10.2.2 Urine Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Nasal and Oropharyngeal Swabs Sample
    • 10.3.1 Overview
    • 10.3.2 Nasal and Oropharyngeal Swabs Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.4 Others
    • 10.4.1 Overview
    • 10.4.2 Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)

11. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by End User

  • 11.1 Hospitals and Clinics
    • 11.1.1 Overview
    • 11.1.2 Hospitals and Clinics: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.1.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Hospitals and Clinics
  • 11.2 Home Care Settings
    • 11.2.1 Overview
    • 11.2.2 Home Care Settings: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.3 Ambulatory and Urgent Care Facilities
    • 11.3.1 Overview
    • 11.3.2 Ambulatory and Urgent Care Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.4 Nursing Home and Assisted Living Facilities
    • 11.4.1 Overview
    • 11.4.2 Nursing Home and Assisted Living Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.5 Research Laboratories
    • 11.5.1 Overview
    • 11.5.2 Research Laboratories: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.6 Diagnostics Centers
    • 11.6.1 Overview
    • 11.6.2 Diagnostics Centers: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)

12. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Distribution Channel

  • 12.1 E-Com Platforms
    • 12.1.1 Overview
    • 12.1.2 E-Com Platforms: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 12.2 Retail Channel and Pharmacies
    • 12.2.1 Overview
    • 12.2.2 Retail Channel and Pharmacies: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • 12.3 Others
    • 12.3.1 Overview
    • 12.3.2 Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)

13. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Country Analysis

  • 13.1 North America
    • 13.1.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Countries
    • 13.1.2 North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue and Forecast and Analysis - by Country
      • 13.1.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue and Forecast and Analysis - by Country
      • 13.1.2.2 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
        • 13.1.2.2.1 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Diseases
        • 13.1.2.2.2 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sexually Transmitted Diseases Testing
        • 13.1.2.2.3 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Tropical Diseases Testing
        • 13.1.2.2.4 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Technology
        • 13.1.2.2.5 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Molecular Diagnostics
        • 13.1.2.2.6 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Polymerase Chain Reactions (PCR)
        • 13.1.2.2.7 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Prescription Testing
        • 13.1.2.2.8 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sample
        • 13.1.2.2.9 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by End User
        • 13.1.2.2.10 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Hospitals And Clinics
        • 13.1.2.2.11 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Distribution Channel
      • 13.1.2.3 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
        • 13.1.2.3.1 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Diseases
        • 13.1.2.3.2 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sexually Transmitted Diseases Testing
        • 13.1.2.3.3 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Tropical Diseases Testing
        • 13.1.2.3.4 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Technology
        • 13.1.2.3.5 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Molecular Diagnostics
        • 13.1.2.3.6 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Polymerase Chain Reactions (PCR)
        • 13.1.2.3.7 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Prescription Testing
        • 13.1.2.3.8 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sample
        • 13.1.2.3.9 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by End User
        • 13.1.2.3.10 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Hospitals And Clinics
        • 13.1.2.3.11 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Distribution Channel
      • 13.1.2.4 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
        • 13.1.2.4.1 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Diseases
        • 13.1.2.4.2 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sexually Transmitted Diseases Testing
        • 13.1.2.4.3 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Tropical Diseases Testing
        • 13.1.2.4.4 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Technology
        • 13.1.2.4.5 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Molecular Diagnostics
        • 13.1.2.4.6 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Polymerase Chain Reactions (PCR)
        • 13.1.2.4.7 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Prescription Testing
        • 13.1.2.4.8 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sample
        • 13.1.2.4.9 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by End User
        • 13.1.2.4.10 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Hospitals And Clinics
        • 13.1.2.4.11 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Distribution Channel

14. North America Point-Of-Care Molecular Testing for Infectious Diseases Market - Industry Landscape

  • 14.1 Overview
  • 14.2 Growth Strategies in North America Point-Of-Care Molecular Testing for Infectious Diseases Market
  • 14.3 Organic Growth Strategies
    • 14.3.1 Overview
  • 14.4 Inorganic Growth Strategies
    • 14.4.1 Overview

15. Company Profiles

  • 15.1 Abbott Laboratories
    • 15.1.1 Key Facts
    • 15.1.2 Business Description
    • 15.1.3 Products and Services
    • 15.1.4 Financial Overview
    • 15.1.5 SWOT Analysis
    • 15.1.6 Key Developments
  • 15.2 Agilent Technologies Inc
    • 15.2.1 Key Facts
    • 15.2.2 Business Description
    • 15.2.3 Products and Services
    • 15.2.4 Financial Overview
    • 15.2.5 SWOT Analysis
    • 15.2.6 Key Developments
  • 15.3 Becton Dickinson and Co
    • 15.3.1 Key Facts
    • 15.3.2 Business Description
    • 15.3.3 Products and Services
    • 15.3.4 Financial Overview
    • 15.3.5 SWOT Analysis
    • 15.3.6 Key Developments
  • 15.4 Bio-Rad Laboratories Inc
    • 15.4.1 Key Facts
    • 15.4.2 Business Description
    • 15.4.3 Products and Services
    • 15.4.4 Financial Overview
    • 15.4.5 SWOT Analysis
    • 15.4.6 Key Developments
  • 15.5 Cardinal Health Inc
    • 15.5.1 Key Facts
    • 15.5.2 Business Description
    • 15.5.3 Products and Services
    • 15.5.4 Financial Overview
    • 15.5.5 SWOT Analysis
    • 15.5.6 Key Developments
  • 15.6 Danaher Corp
    • 15.6.1 Key Facts
    • 15.6.2 Business Description
    • 15.6.3 Products and Services
    • 15.6.4 Financial Overview
    • 15.6.5 SWOT Analysis
    • 15.6.6 Key Developments
  • 15.7 Cue Health Inc
    • 15.7.1 Key Facts
    • 15.7.2 Business Description
    • 15.7.3 Products and Services
    • 15.7.4 Financial Overview
    • 15.7.5 SWOT Analysis
    • 15.7.6 Key Developments
  • 15.8 QuidelOrtho Corp
    • 15.8.1 Key Facts
    • 15.8.2 Business Description
    • 15.8.3 Products and Services
    • 15.8.4 Financial Overview
    • 15.8.5 SWOT Analysis
    • 15.8.6 Key Developments
  • 15.9 Thermo Fisher Scientific Inc
    • 15.9.1 Key Facts
    • 15.9.2 Business Description
    • 15.9.3 Products and Services
    • 15.9.4 Financial Overview
    • 15.9.5 SWOT Analysis
    • 15.9.6 Key Developments
  • 15.10 F. Hoffmann-La Roche Ltd
    • 15.10.1 Key Facts
    • 15.10.2 Business Description
    • 15.10.3 Products and Services
    • 15.10.4 Financial Overview
    • 15.10.5 SWOT Analysis
    • 15.10.6 Key Developments

16. Appendix

  • 16.1 About The Insight Partners
  • 16.2 Glossary of Terms
    • 1.1.1

List Of Tables

  • Table 1. North America Point-of-Care Molecular Testing for Infectious Diseases Market Segmentation
  • Table 2. Infectious Diseases and Fundings
  • Table 3. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Table 4. Market Share Analysis, By Companies (2023)
  • Table 5. Pricing Analysis
  • Table 6. List of Patent filed by Companies
  • Table 7. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Diseases
  • Table 8. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sexually Transmitted Diseases Testing
  • Table 9. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Tropical Diseases Testing
  • Table 10. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Technology
  • Table 11. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Molecular Diagnostics
  • Table 12. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Polymerase Chain Reactions (PCR)
  • Table 13. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Prescription Testing
  • Table 14. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sample
  • Table 15. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 16. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Hospitals and Clinics
  • Table 17. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 18. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Country
  • Table 19. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Diseases
  • Table 20. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sexually Transmitted Diseases Testing
  • Table 21. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Tropical Diseases Testing
  • Table 22. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Technology
  • Table 23. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Molecular Diagnostics
  • Table 24. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Polymerase Chain Reactions (PCR)
  • Table 25. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Prescription Testing
  • Table 26. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sample
  • Table 27. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 28. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Hospitals And Clinics
  • Table 29. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 30. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Diseases
  • Table 31. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sexually Transmitted Diseases Testing
  • Table 32. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Tropical Diseases Testing
  • Table 33. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Technology
  • Table 34. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Molecular Diagnostics
  • Table 35. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Polymerase Chain Reactions (PCR)
  • Table 36. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Prescription Testing
  • Table 37. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sample
  • Table 38. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 39. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Hospitals And Clinics
  • Table 40. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 41. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Diseases
  • Table 42. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sexually Transmitted Diseases Testing
  • Table 43. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Tropical Diseases Testing
  • Table 44. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Technology
  • Table 45. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Molecular Diagnostics
  • Table 46. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Polymerase Chain Reactions (PCR)
  • Table 47. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Prescription Testing
  • Table 48. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sample
  • Table 49. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 50. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Hospitals And Clinics
  • Table 51. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 52. Recent Organic Growth Strategies in North America Point-Of-Care Molecular Testing for Infectious Diseases Market
  • Table 53. Recent Inorganic Growth Strategies in the North America Point-Of-Care Molecular Testing For Infectious Diseases Market
  • Table 54. Glossary of Terms, Infectious Disease Diagnostics Market
    • 1.1.2

List Of Figures

  • Figure 1. North America Point-of-Care Molecular Testing for Infectious Diseases Market Segmentation, by Country
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue (US$ Million), 2021-2031
  • Figure 5. Pre and Post COVID-19 Impact
  • Figure 6. Patents filed by Top Companies for POC
  • Figure 7. Number of Patent Families for POC
  • Figure 8. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) - by Diseases, 2023 and 2031
  • Figure 9. HIV Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Influenza Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Sexually Transmitted Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Hepatitis C Virus Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Tropical Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Respiratory Infection Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Hospital Acquired Infections: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Strep: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) - by Technology, 2023 and 2031
  • Figure 19. Lateral Flow Assay: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Dipsticks: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Microfluidics: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Molecular Diagnostics: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Immunoassays: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Solid Phase: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) - by Prescription Testing, 2023 and 2031
  • Figure 27. Prescription Based Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 28. OTC Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 29. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) - by Sample, 2023 and 2031
  • Figure 30. Blood Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 31. Urine Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 32. Nasal and Oropharyngeal Swabs Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 33. Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 34. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) - by End User, 2023 and 2031
  • Figure 35. Hospitals and Clinics: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 36. Home Care Settings: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 37. Ambulatory and Urgent Care Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 38. Nursing Home and Assisted Living Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 39. Research Laboratories: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 40. Diagnostics Centers: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 41. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) - by Distribution Channel, 2023 and 2031
  • Figure 42. E-Com Platforms: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 43. Retail Channel and Pharmacies: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 44. Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 45. North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Key Countries, 2023 and 2031 (%)
  • Figure 46. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 47. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 48. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 49. Growth Strategies in North America Point-Of-Care Molecular Testing for Infectious Diseases Market